Ervebo Vaccine Latest News
Recently, the World Health Organisation and its partners said that Congo will receive 70,000 doses of the Ervebo vaccine.
About Ervebo Vaccine
- It is licensed for use against the Ebola virus disease.
- It is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (VSV) vaccine.
- Working
- The vaccine only contains one protein from the Zaire Ebola virus and cannot cause Ebola virus disease.
- When a person receives the vaccine, it triggers an immune response against this viral protein.Â
- Administration: It is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease.Â
- It is manufactured by Merck.
- It does not provide protection against other species of orthoebolaviruses or orthomarburgviruses.
Key Facts about Ebola
- It is a severe and often deadly viral disease caused by a group of viruses known as orthoebolaviruses (formerly ebolavirus).
- It is a severe contagious disease affecting humans and non-human primates.Â
- Ebola, first identified in 1976 in southern Sudan and the Democratic Republic of Congo, primarily affects remote villages in Central and West Africa. Â
- It is known as a hemorrhagic fever virus because it can cause problems with the clotting system of the body and lead to internal bleeding as blood leaks from small blood vessels.
- Transmission
- The virus is transmitted to people from wild animals (such as fruit bats, porcupines, and non-human primates).
- It then spreads in the human population through direct contact with the blood, secretions, organs, or other bodily fluids of infected people and with surfaces and materials contaminated with these fluids.
- Ebola cannot be transmitted by air.
- Symptoms
- Incubation period: Typically 5 to 15 days; range is 2 to 21 days.Â
- Symptoms include fever, diarrhea, vomiting, bleeding, and often, death.
Source: IT
Ervebo Vaccine FAQs
Q1: ERVEBO was developed by whom?
Ans: Merck
Q2: ERVEBO vaccine protects against which strain of Ebola virus?
Ans: Zaire ebolavirus